Vitaros

Apricus Biosciences Inc (NASDAQ: APRI) receded 67.4 percent Friday and continued down Tuesday after the U.S. Food and Drug Administration issued a response letter for Vitaros. The FDA declined to approve the New Drug Application after identifying safety concerns and deficiencies in the erectile...

Although the action was light on the FDA approval front, biotech stocks took the spotlight in January, thanks to a few multi-billion-dollar deals announced in the space. Celgene Corporation (NASDAQ: CELG) announced a deal to buy Juno Therapeutics Inc (NASDAQ: JUNO). Ahead of that deal,...